A Functional Cure for HIV/AIDS Might Now Be In Sight
December 1, 2017
| by Samantha Bonar
Currently, more than 34 million people are living with HIV/AIDS worldwide. Nearly 1.1 million of these individuals are in the U.S., and an estimated 18,000 Americans still die of HIV/AIDS each year.
The good news is that the incidence of death from HIV infection continues to drop. Researchers – including experts at City of Hope – are making massive strides
in preventing and treating the disease. For many, HIV/AIDS no longer is a death sentence. With the proper therapy, it can be managed as a chronic condition for many patients.
In 10 years, cellular therapy will become a functional cure for HIV,” said Zaia, the Aaron D. Miller and Edith Miller Chair in Gene Therapy. “Meaning you don’t have to take any medications, but you still may have the virus. Your immune system will be able to control it.”
Stem cell and gene therapy for HIV are two of the cellular therapies that offer great promise. Gene editing is one approach currently being tested in clinical trials at City of Hope.
The approach uses an enzyme called a zinc-finger nuclease as a pair of molecular “scissors” that can edit the HIV patient’s stem cell genes so that they no longer produce a key protein the virus requires to infect cells. It aims to spur the immune system to produce T cells resistant to HIV by infusing the patient with these altered stem cells.
“It’s the first use of editing of the stem cell. It’s a big trial,” Zaia said. “We’re literally cutting the gene itself. It destroys that gene permanently. If we could get this to work, it would be a single treatment that would be curative. You wouldn’t have to take medications.”
However, the trick is getting the cells to replicate. And the technique only works on one version of the HIV virus.
“There are patients who have other forms of the virus that can use other genes to get into a T cell,” Zaia said. “But the concept is pretty amazing. We’ve performed this on some patients and we are learning from them.”
Since the technique requires a complete stem cell transplant, patients are informed of the considerable risks and then vetted through a meticulous, multiweek Food and Drug Administration-mandated screening process.
“Explaining the risks is important,” Zaia said. “It's revolutionary to even consider stem cell transplants for patients who don't otherwise desperately need them, say for leukemia treatment.”
Another approach being studied at City of Hope inserts new genes into blood stem cells to deactivate the genes that HIV needs for infection. The new genes are taken from an inactive virus called a lentivirus. This technique is a little more complicated and involves AIDS patients who also have lymphoma.
“We’re taking lymphoma patients who are cured and we say, ‘Now that you’re cured of lymphoma, why don’t we try to cure your HIV?’” Zaia said. By infusing them with the genetically modified cells, “We are asking the question, ‘Will they show up in the peripheral blood, and can you do this safely?’” The technique has only been tried in two patients so far and the results are not yet available.
Finally, investigators at City of Hope are “editing” the immune system’s T cells to control HIV infection. These cells, called ‘CAR T cells’ could directly protect the patient without the need for a transplant.
“I think the field of HIV research is changing so fast, and, as we improve our methods, we have other things coming along that are going to be even better than the current trials,” Zaia said.
“It’s an exciting time to be a part of this effort.”
Click here to learn more about City of Hope's groundbreaking HIV/AIDS research. If you are looking for a second opinion or consultation about your treatment, request an appointment online or contact us at 800-826-HOPE. Please visit Making Your First Appointment for more information.
, Thank you for supporting our mission of eliminating cancer and other life-threatening diseases! Make sure to check your inbox from time to time for the latest City of Hope updates and breakthroughs.
You may also be interested in